Pipeline Database
UB497
Search clinical-stage assets by therapeutic area, modality, target, indication, stage and territory — then inquire on any row that fits your brief.
UB497
IndicationsCervical intraepithelial neoplasia
ClinicalCN - I
TherapeuticsOncology
ModalitiesCGT
Exclusive Summary
- Pioneering mRNA Asset: The first therapeutic mRNA vaccine approval for clinical trials targeting Cervical Intraepithelial Neoplasia (CIN) in China, demonstrating leading technological status.
- Addressing Critical Unmet Need: Offers a non-invasive therapeutic alternative to surgical procedures (LEEP/conization), preserving fertility and reducing reproductive risks for women.
- Validated Regulatory Status: Successfully obtained IND approval from the Chinese NMPA in July 2024 as a Class 1 New Drug, de-risking the initial regulatory pathway.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →